Income Statement

KAIROS PHARMA, LTD.

KAPA

Performance Overview Click any row in the table to add it to this chart

in millions USD

Metric	Dec 31, 2025 2025 FY	Dec 31, 2024 2024 FY
Revenue	100.00	100.00
Cost of Revenue	-	-
Gross Profit	100.00	100.00
Operating Expenses	5.57	2.34
Research & Development	2.14	0.41
Selling, General & Administrative	3.44	1.93
Other Operating Expenses	-	-
Operating Income	94.43	97.66
Non-Operating Income	0.13	-0.26
Interest Income	-	-
Interest Expense	-	-
Other Non-Op Income / Expense	-	-
Income Before Tax	-	-
Income Tax Expense	-	-
Non-Controlling Interest	-	-
Net Income	-5.45	-2.60

Supplemental Per share data, derived & other items — not part of the income statement

in millions USD unless noted